Close
Advanced Search

Abstract

In 1996 the Committee for Proprietary Medicinal Products published their ‘Points to consider’ which have been used as unofficial guidelines by drug companies developing new pharmacologic compounds. Recommendaitons endorsed by the CPMP regarding hand measurement of the QT interval, QT dispersion, the Bazett QT interval correction for heart rate and the use of signal values for QTc changes compared to baseline are discussed in this paper.

‘Points to consider’, QT interval measurements

References

[1]
Monahan
BP
, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena LR. Torsades de pointes occurring in association with terfenadine use.
J Am Med Assoc
 .
1990
;
264
:
2788
–2790
[2]
Woosley
RL
, Chen YC, Freiman JP, Gillis RA. Mechanism of the cardiotoxic actions of terfenadine.
J Am Med Assoc
 .
1993
;
269
:
1532
–1536
[3]
Honig
PK
, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Terfenadine-ketoconazole interaction pharmacokinetic and electrocardiographic consequences.
J Am Med Assoc
 .
1993
;
269
:
1513
–1518
[4]
Committee for Proprietary Medical Products (CPMP). Points to Consider: The assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. The European Agency for Evaluation of Medicinal Products. December 1997.
Google Scholar
[5]
McLaughlin
NB
, Campbell WE, Murray A. Comparison of automatic QT measurement techniques in the normal 12 lead electrocardiogram.
Br Heart J
 .
1995
;
74
:
84
–89
[6]
Surawicz
B
. Will QT dispersion play a role in clinical decision-making?
J Cardiovasc Electrophysiol
 .
1996
;
7
:
777
–784
[7]
Funck-Brentano
C
, Jaillon P. Rate-corrected QT interval: Techniques and limitations.
Am J Cardiol
 .
1993
;
72
:
17B
–22B
[8]
Hnatkova
K
, Malik M. ‘Optimum’ formulae for heart rate correction of the QT interval.
PACE
 .
1999
;
22
:
1683
–1687
Topic:
Issue Section:
Articles
Download all figures